Clinical Trials Logo

Colitis, Ulcerative clinical trials

View clinical trials related to Colitis, Ulcerative.

Filter by:

NCT ID: NCT05578508 Withdrawn - Crohn's Disease Clinical Trials

Stem Cells for the Treatment of Pouchitis

Start date: April 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and feasibility of using allogeneic bone marrow derived mesenchymal stem cells (MSCs) to treat people with medically refractory Pouchitis.

NCT ID: NCT05575505 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.

Start date: February 2, 2023
Phase: Phase 2
Study type: Interventional

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa; however, the exact underlying mechanisms of UC remain poorly understood. Also, it is associated with high risk of colon cancer, so there is a continuous need for introducing new therapies that decrease progression, and hence better outcomes

NCT ID: NCT05574387 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Metformin as Added on Therapy in Patients With Ulcerative Colitis

Start date: January 20, 2023
Phase: Phase 2
Study type: Interventional

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is marked by increased intestinal motility and bloody diarrhea. The clinical value of existing therapeutic strategies of UC, including glucocorticoids, anti-tumor necrosis factor α (TNF-α), mesalamine, and thiopurines is still limited. Therefore, the discovery of new therapeutic approaches is essential to improve the effectiveness of the treatment.Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a conserved fuel-sensing enzyme that plays an important role in the regulation of cellular metabolism where it increases glucose and fatty acids uptake and activates the oxidation process to improve the cellular energy utilization

NCT ID: NCT05570006 Recruiting - Ulcerative Colitis Clinical Trials

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

Start date: March 16, 2023
Phase: Phase 2
Study type: Interventional

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective ABBV-668 is in treating adult participants with UC. Adverse events and change in disease activity will be assessed. ABBV-668 is an investigational drug being developed for the treatment of moderate to severe UC. Approximately 40 adult participants diagnosed with UC will be enrolled in approximately 30 sites globally. Participants will receive oral capsules of ABBV-668 twice daily for 52-weeks and will undergo a 30 day follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

NCT ID: NCT05567068 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

Statins exert numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of their basic lipid-lowering properties.

NCT ID: NCT05561738 Recruiting - Ulcerative Colitis Clinical Trials

Nicotinamide Riboside in Ulcerative Colitis

Start date: February 28, 2024
Phase: N/A
Study type: Interventional

This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).

NCT ID: NCT05561062 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Atorvastatin in Patients With Ulcerative Colitis

Start date: December 1, 2022
Phase: Phase 2
Study type: Interventional

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa; however, the exact underlying mechanisms of UC remain poorly understood. Statins exert numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of their basic lipid-lowering property.

NCT ID: NCT05558761 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis

Start date: October 10, 2022
Phase: Phase 2
Study type: Interventional

The exact underlying mechanisms of ulcerative colitis (UC), an idiopathic, chronic inflammatory disease marked by diffused inflammation of the colon and rectum mucosa, are still unknown. Due to genetic, immune, and environmental factors, UC is highly dependent on cellular immune reactions and exaggerated inflammatory responses. The release of several cytokines, kinins, leukotrienes, platelet-activating factor (PAF), and reactive oxygen species is connected to immunological activity (ROS). Additionally, many of the cytokines will start an acute phase response, making the inflammation worse.

NCT ID: NCT05553704 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Metformin in Patients With Ulcerative Colitis Treated With Mesalamine

Start date: November 1, 2022
Phase: Phase 2
Study type: Interventional

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa, however, the exact underlying mechanisms of UC remain poorly understood.UC is strongly dependent on cellular immune reaction and exaggerated inflammatory response due to genetic, immune and environmental factors.

NCT ID: NCT05549323 Active, not recruiting - Ulcerative Colitis Clinical Trials

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

Start date: November 7, 2022
Phase: Phase 1
Study type: Interventional

This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.